For ten years, Xinglong Wang and his team at the University of Arizona asked a simple question that no one else had tried to answer: Could there be one tiny part of a key protein causing all the harm in ALS, something a drug could switch off without disturbing everything else? That question led them to an experimental drug called XL20, and the results are giving scientists fresh hope for tackling a disease that has resisted treatment for decades.
ALS, also known as Lou Gehrig's disease, became a household name in 2014 through the viral Ice Bucket Challenge, where millions of people poured ice water over their heads to raise money and awareness. Despite that outpouring of support, ALS still has no known cure, and the few treatments approved by the FDA only modestly help patients. "There is an urgent need for a real breakthrough," Wang said.
Most cases of ALS — more than 90% — occur without any family history or clear genetic cause. But nearly every patient, whether inherited or not, shares one telltale sign: a protein called TDP-43 clumps abnormally inside their nerve cells. Wang's team focused on this protein because it shows up in almost every case. In healthy cells, TDP-43 stays where it belongs. In ALS, it drifts out of place and forms toxic clumps that damage the nerve cells controlling movement.
The researchers spent a decade hunting for the exact trouble spot. They found a small region of TDP-43 where many disease-causing mutations cluster, and this region looked nearly identical across species, from mice to humans. When the team deleted this region in mice, nerve cell death dropped sharply — and the protein's normal functions stayed intact. After testing and retesting, they created XL20, a drug that latches onto this harmful region. Crucially, XL20 can cross the blood-brain barrier, the tight filter that keeps most medicines out of the brain.
In mice with ALS-like symptoms, XL20 extended median survival by about a week — a meaningful gain given mice's short lifespan. The drug also protected nerve cells and reduced muscle weakness. Even more promising, when the team tested XL20 on human motor neurons in the lab — the specialized nerve cells in the brain and spinal cord that ALS destroys — it reversed some of the same damage seen in patients.
Because XL20 targets TDP-43 directly and already works in human cells, Wang says it represents a promising candidate for future clinical development. The findings may also reach beyond ALS. The same TDP-43 abnormality plays a role in LATE, a common age-related dementia affecting roughly 1 in 3 people over 85. A drug that addresses the root problem could potentially help millions more.
The road from mouse studies to human treatments is long and uncertain. But after a decade of patient work, scientists now have a new target — and a new candidate drug — to explore.